Search

Your search keyword '"Andolina M."' showing total 14 results
Start Over Author "Andolina M." Topic business
14 results on '"Andolina M."'

1. COVID-19 in Italian patients with rheumatic autoimmune systemic diseases

Author

Ferri, C., Giuggioli, D., Raimondo, V., Fallahi, P., Antonelli, A., Spinella, A., Brittelli, R., Aiello, V., Caminiti, R., L'Andolina, M., Tavoni, A., Bilia, S., Giannini, D., Mariano, G. P., Cecchetti, R., Guiducci, S., Bellando-Randone, S., Ursini, F., Brusi, V., Meliconi, R., Caminiti, M., Varcasia, G., Ferrari, T., Gigliotti, P., Pellegrini, R., Olivo, D., Colaci, M., Murdaca, G., Ferri C., Giuggioli D., Raimondo V., Fallahi P., Antonelli A., Spinella A., Brittelli R., Aiello V., Caminiti R., L'Andolina M., Tavoni A., Bilia S., Giannini D., Mariano G.P., Cecchetti R., Guiducci S., Bellando-Randone S., Ursini F., Brusi V., Meliconi R., Caminiti M., Varcasia G., Ferrari T., Gigliotti P., Pellegrini R., Olivo D., Colaci M., and Murdaca G.

Subjects
0301 basic medicine, Pediatrics, medicine.medical_specialty, rheumatoid, Population, Immunology, Arthritis, autoimmune disease, Disease, Scleroderma, General Biochemistry, Genetics and Molecular Biology, 03 medical and health sciences, Psoriatic arthritis, 0302 clinical medicine, Rheumatology, Pandemic, medicine, Immunology and Allergy, autoimmune diseases, scleroderma, education, Spondylitis, 030203 arthritis & rheumatology, education.field_of_study, business.industry, spondylitis, systemic, medicine.disease, arthriti, ankylosing, arthritis, psoriatic, 030104 developmental biology, spondyliti, business, Cohort study
Abstract

We followed with great interest the numerous reports published by the Annals 1–9 as regards the impact of the COVID-19 pandemic on different rheumatic autoimmune systemic diseases (ASD), including the survey study by Costa et al 9 that underlined the usefulness of telerheumatology in the management of patients with psoriatic arthritis in COVID-19 era. On the same topic, the world literature encompasses a large number of anecdotal observations, cohort studies and telephone surveys.1–15 Overall, the observed prevalence of symptomatic COVID-19, usually as mild-moderate disease, in patients with chronic arthritis was comparable to that found in the general population, while worse outcomes represented almost rare events.1–15 Conversely, increased percentages of symptomatic COVID-19 were observed in patient cohorts with connective tissue diseases, especially systemic lupus or systemic vasculitis.6 7 Of note, in ASD complicated by COVID-19, the baseline use of immune modifiers, namely, conventional synthetic (csDMARD), biological (bDMARD) and targeted synthetic disease-modifying antirheumatic drugs (tsDMARD), was not associated with worse COVID-19 disease outcomes.3–5 9 10 Almost invariably these monocentre studies focused on ASD patients’ populations from limited geographical areas.1–15 Given the heterogeneous distribution of pandemic infection within the same country, we investigated the impact of COVID-19 in ASD patients’ populations from three distinct regions of Italy (northern, Emilia Romagna; central, Tuscany; and southern, Calabria), characterised by different spread of the COVID-19 pandemic, prevalent in northern Italy with a marked gradient north-south.16 Our 6-week multicentre telephone survey of 1641 unselected patients with ASD confirmed the quite benign clinical course of COVID-19 in ASD, along with the safety of baseline use of either …

Published
2020
Full Text
View/download PDF

2. Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: Influence of dose and stem cell source shows better outcome with rich marrow

Author

Gorin N.C., Labopin M., Rocha V., Arcese W., Beksac M., Gluckman E., Ringden O., Ruutu T., Reiffers J., Bandini G., Falda M., Zikos P., Willemze R., Frassoni F., Abecasis M., Abráhamová J., Afanassiev B.V., Aglietta M., Alabdulaaly A., Aleinikova O., Paolo Alessandrino E., Al Shemmari S.H., Amadori D., Amadori S., Amos T., Andolina M., Andreesen R., Angelucci E., Anhuf J., Arnold R., Arpaci F., Attal M., Azevedo W., Azim H.A., Baccarani M., Bacigalupo A., Barbui T., Bargetzi M., Barnard D.L., Bartsch H.H., Baruchel A., Battista C., Bay J.-O., Bayik M., Bazarbachi A., Beguin Y., López J.L.B., Benedek I., Benedetti F., Bengala C., Berrebi A., Besalduch J., Biesma D., Biron P., Björkholm M., Blaise D., Blesing N.E., Boasson M., Bobev D., Boccadoro M., Bolaman Z., Boogaerts M.A., Bordessoule D., Bosi A., Aida B.S., Bourhis J.H., Bourikas G., Bowen D.T., Bregni M., Bries G., Brinch L., Brittain D., Bron D., Brune M., Bullorsky E.O., Bunjes D., Burdach S., Burnett A.K., Buzyn A., Caballero D., Cagirgan S., Cahn J.-Y., Canepa C.O., Cao A., Carella A.M., Carrera F.D., Carret A.-S., Cascinu S., Castel V., Caswell M., Cavanna L., Cetto G.L., Chapuis B., Chasty R., Chen Y.-C., Chisesi T., Chopra R., Chybicka A., Clark R.E., Colombat P., Colovic M.D., Constenla-Figueiras M., Contreras M., Contu L., Cordonnier C., Cornelissen J.J., Cornish J., Coser P., Costa N., Coze C., Craddock C., Crown J., Culligan D.J., Danova M., Darbyshire P.J., Davies J.M., de Bock R., de Pablos Gallego J.M., De Prijck B., de Revel T., De Rossi G., De Souza C.A., Deb G., Degos L., Demuynck H., Dervenoulas I., Di Bartolomeo P., Di Renzo N., Diaz M.A., Diehl V., Diez-Martin J.L., Dincer S., Giorgio D., Dmoszynska A., Doelken G., Peter P.D., Dulley F., Easow J., Ebell W., Efremidis A., Ehninger G., Eichler H., Eimermacher H., Enno A., Errazquin L., Aguado J.E., Everaus H., Fagioli F., Fanin R., Fassas A., Fasth A., Faulkner L.B., Fauser A.A., Feldman L., Feremans W., Ferhanoglu B., Fernández M.N., Fernández-Ranada J.M., Ferrant A., Ferrara F., Finke J., Fischer A., Fischer J., Fitzsimons T., Floristan F., Forjaz de Lacerda J.M.F., Fossati-Bellani F., Fosser V., Franklin I., Freund M., Frickhofen N., Gabbas A., Gadner H., Gallamini A., Galvin M.C., López J.G., García-Conde J., Gaska T., Gastl G., Gedikoglu G., Ghavamzadeh A., Gianni A., Gibson B.E., Gil J.L., Gilleece M.H., Gisselbrecht C., Glass B., Gmür J., Göbel U., Goldman J.M., Goldstone A.H., San Miguel J.D.G., González-López M.-A., Grafakos S., Gramatzki M., Grañena A., Gratecos N., Gratwohl A., Greinix H.T., Gugliotta L., Guilhot F., Guimaraes J.E., Gülbas Z., Gulyuz O., Gurman G., Gutierrez M.M., Haas R., Hamladji R.-M., Hamon M.D., Hansen N.E., Harhalakis N., Harousseau J.L., Hartenstein R., Hartmann C.O., Hausmaninger H., Haznedar R., Heit W., Hellmann A., Herrmann R.P., Hertenstein B., Hess U., Hinterberger W., Ho A.D., Hoelzer D., Holowiecki J., Horst H.-A., Hossfeld D.K., Huebsch L., Hunter A.E., Iacopino P., Iannitto E., Indrák K., Iriondo A., Izzi T., Jackson G.L., Jacobs P., Jacobsen N., Janvier M., Jebavy L., Joensuu H., Joerg S., Jones F.G.C., Jouet J.P., Joyner M.V., Juliusson G., Jürgens H., Kalayoglu-Besisik S., Kalman N., Kalmanti M., Kansoy S., Kansu E., Kanz L., Karianakis G., Kernéis Y., Khalifeh O., Khomenko V., Kienast J., Killick S., Kirchner H.H., Klingebiel T., Knauf W., Koenigsmann M., Koistinen P., Koivunen E., Kolb H.-J., Kolbe K., Koller E., Komarnicki M., Koscielniak E., Kovacsovics T., Kowalczyk J.R., Koza V., Kozak T., Kugler J., Kuliczkowski K., Kvaloy S., Labar B., Laciura P., Palacios J.J.L., Lakota J., Lambertenghi D.G., Lange A., Lanza F., Isasti R.L., Lauria F., Le Moine F., Leblond V., Lelli G., Lenhoff S., Leon L.A., Leoncini-Franscini L., Leone G., Leoni P., Levis A., Leyvraz S., Liberati M., Link H., Linkesch W., Liso V., Lisukov I.A., Littlewood T., Ljungman P., Locatelli F., Losonczy H., Lotz J.-P., Ludwig H., Lukac J., Lutz D., Macchia P., Madrigal A., Maiolino A., Majolino I., Eloy-García J.M., Malesevic M., Mandelli F., Marc A., Marcus R., Marianska B., Markuljak I., Marsh J.C.W., Martelli M.F., Marti Tutusaus J.M., Martin S., Martin M., Martinelli G., Martínez-Rubio A.M., Martoni A., Maschan A., Maschmeyer G., Masszi T., Mazza P., McCann S., Meier C.R., Messina C., Mettivier V., Metzner B., Michallet M., Michieli M., Michon J., Milligan D.W., Milone J.H., Giuseppe G.M., Minigo H., Mistrik M., Moicean A.D., Monfardini S., Montserrat E., Moraleda Jimenez J.M., Morales-Lazaro A., Morandi S., Morra E., Mufti G.J., Musso M., Nagler A., Nalli G., Naparstek E., Narni F., Nenadov-Beck M., Neubauer A., Newland A.C., Niederwieser D., Niethammer D., Noens L.A., Nousiainen T., Novik A., Novitzky N., Occhini D., Odriozolas J., Ojanguren J.M., O’meara A., Onat H., Orchard K., Ortega J.J., Osieka R., Ossenkoppele G.J., Othman B., Ovali E., Ozcebe O.I., Ozerkan K., Ozturk A., Papatryfonos A., Parker J.E., Pastore M., Patrone F., Patton N., Pejin D., Peñarrubia M.J., Equiza E.P., Peschel C., Pession A., Pigaditou A., Pignon B., Pihkala U., Pimentel P., Pitini V., Podoltseva E., Pogliani E.M., Anna A.P., Porta F., Potter M., Powles R., Prentice G.H., Pretnar J., Ptushkin V., Quarta G., Reiter A., Remes K., Reykdal S., Santasusana J.M.R., Rifón J., Rio B., Rizzoli V., Robak T., Robinson A.J., Rodeghiero F., Rodríguez Fernández J.M., Rombos Y., Romeril K.R., Rosenmayr A., Rossi J.F., Rosti G., Rotoli B., Rowe J.M., Russell N.H., Ryzhak O., Rzepecki P., Saglio G., Salwender H., Samonigg H., Santoro A., Sanz M.A., Sayer H.G., Scanni A., Schaafsma M.R., Schaefer U.W., Schanz U., Schattenberg A., Schey S.A.M., Schlimok G., Schmoll H.-J., Schots R., Schouten H., Schwarer A.P., Schwerdtfeger R., Scimè R., Segel E., Seger R., Selleslag D., Serban M., Shamaa S., Shaw P.J., Siegert W., Siena S., Sierra J., Simonsson B., Singer C.R.J., Sirchia G., Skotnicki A.B., Slavin S., Snowden J., Sotto J.J., Tanyeli A., Tedeschi L., Tidefelt U., Tissot J.-D., Tobler A., Tomas J.F., Torres J.P., Torres G.A., Touraine J.-L., Trneny M., Uderzo C., Unal E., Unal A., Undar L., Urban C., Van den Berg H., van Marwijk K.M., Vellenga E., Venturini M., Verdonck L.F., Veys P., Vilardell J., Vinante O., Visani G., Vitek A., Vivancos P., Volpe E., Vora A., Vorlicek J., Vowels M., Vujic D., Wachowiak J., Wagner T., Wahlin A., Walewski J., Wandt H., Weissinger F., Wijermans P.W., Wiktor-Jedrzejczak W., Will A.M., Woell E., Wörmann B., Yaniv I., Yesilipek M.A., Yilmaz U., Yong A., Zachée P., Zambelli A., Zander A.R., Zintl F., Zoumbos N.C., Çukurova Üniversitesi, Maltepe Üniversitesi, and Ege Üniversitesi

Subjects
Myeloid, Male, Pathology, Time Factors, Graft vs Host Disease, Biochemistry, Gastroenterology, Blood cell, Bone Marrow, Child, Bone Marrow Transplantation, Leukemia, Remission Induction, Hematology, Middle Aged, Prognosis, Leukemia, Myeloid, Acute, ComputingMilieux_MANAGEMENTOFCOMPUTINGANDINFORMATIONSYSTEMS, medicine.anatomical_structure, Treatment Outcome, Child, Preschool, Female, Stem cell, InformationSystems_MISCELLANEOUS, Homologous, Adult, medicine.medical_specialty, Adolescent, Immunology, Acute, Disease-Free Survival, Internal medicine, medicine, Transplantation, Homologous, Humans, Preschool, Aged, Transplantation, business.industry, ComputerSystemsOrganization_COMPUTER-COMMUNICATIONNETWORKS, Cell Biology, medicine.disease, Peripheral blood, Histocompatibility, Multivariate Analysis, Stem Cell Transplantation, ComputingMethodologies_PATTERNRECOGNITION, Myelocytic leukemia, Bone marrow, business, Settore MED/15 - Malattie del Sangue
Abstract

PubMed ID: 12829583, Several studies have compared bone marrow (BM) and peripheral blood (PB) as stem cell sources in patients receiving allografts, but the cell doses infused have not been considered, especially for BM. Using the ALWP/EBMT registry, we retrospectively studied 881 adult patients with acute myelocytic leukemia (AML), who received a non-T-depleted allogeneic BM (n = 515) or mobilized PB (n = 366) standard transplant, in first remission (CR1), from an HLA-identical sibling, over a 5-year period from January 1994. The BM cell dose ranged from 0.17 to 29 × 10 8 /kg with a median of 2.7 × 10 8 /kg. The PB cell dose ranged from 0.02 to 77 × 10 8 /kg with a median of 9.3 × 10 8 /kg. The median dose for patients receiving BM (2.7 × 10 8 /kg) gave the greatest discrimination. In multivariate analyses, high-dose BM compared to PB was associated with lower transplant-related mortality (RR = 0.61; 95% CI, 0.39-0.98; P = .04), better leukemia-free survival (RR = 0.65; 95% CI, 0.46-0.91; P = .013), and better overall survival (RR = 0.64; 95% CI, 0.44-0. 92; P = .016). The present study in patients with AML receiving allografts in first remission indicates a better outcome with BM as compared to PB, when the dose of BM infused is rich. © 2003 by The American Society of Hematology.

Published
2003

3. Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients' subgroups

Author

Domenico Olivo, E. Pigatto, Francesca La Gualana, Giorgio Amato, Ilaria Cavazzana, Rosario Foti, Antonio Tavoni, Raffaele Brittelli, Tommaso Ferrari, Francesco Masini, Marcella Visentini, Stefano Angelo Santini, Dilia Giuggioli, Franco Franceschini, Vincenzo Raimondo, Laura Gragnani, Giuseppa Pagano Mariano, Poupak Fallahi, Vincenzo Aiello, Lorenzo Puccetti, C. Naclerio, Riccardo Meliconi, Giovanna Cuomo, Amelia Spinella, Ylenia Dal Bosco, Alessandro Antonelli, Daniela Scorpiniti, M. Vadacca, Piero Ruscitti, Milvia Casato, Elisa Visalli, Florenzo Iannone, Maurizio Caminiti, Fabio Cacciapaglia, Francesco Ursini, Clodoveo Ferri, T. Urraro, Rodolfo Caminiti, Monica Monti, Massimo L'Andolina, Giovanni Rechichi, Anna Linda Zignego, Roberto Giacomelli, Giuseppe Varcasia, Roberta Pellegrini, Franco Cozzi, Pietro Gigliotti, Giusy Elia, Ferri, C., Ursini, F., Gragnani, L., Raimondo, V., Giuggioli, D., Foti, R., Caminiti, M., Olivo, D., Cuomo, G., Visentini, M., Cacciapaglia, F., Pellegrini, R., Pigatto, E., Urraro, T., Naclerio, C., Tavoni, A., Puccetti, L., Varcasia, G., Cavazzana, I., L'Andolina, M., Ruscitti, P., Vadacca, M., Gigliotti, P., La Gualana, F., Cozzi, F., Spinella, A., Visalli, E., Dal Bosco, Y., Amato, G., Masini, F., Pagano Mariano, G., Brittelli, R., Aiello, V., Caminiti, R., Scorpiniti, D., Rechichi, G., Ferrari, T., Monti, M., Elia, G., Franceschini, F., Meliconi, R., Casato, M., Iannone, F., Giacomelli, R., Fallahi, P., Santini, S. A., Zignego, A. L., Antonelli, A., Ferri C., Ursini F., Gragnani L., Raimondo V., Giuggioli D., Foti R., Caminiti M., Olivo D., Cuomo G., Visentini M., Cacciapaglia F., Pellegrini R., Pigatto E., Urraro T., Naclerio C., Tavoni A., Puccetti L., Varcasia G., Cavazzana I., L'Andolina M., Ruscitti P., Vadacca M., Gigliotti P., La Gualana F., Cozzi F., Spinella A., Visalli E., Dal Bosco Y., Amato G., Masini F., Pagano Mariano G., Brittelli R., Aiello V., Caminiti R., Scorpiniti D., Rechichi G., Ferrari T., Monti M., Elia G., Franceschini F., Meliconi R., Casato M., Iannone F., Giacomelli R., Fallahi P., Santini S.A., Zignego A.L., and Antonelli A.

Subjects
Male, History, Polymers and Plastics, Binding Antibody Units, BAU, Antibodies, Viral, Gastroenterology, Industrial and Manufacturing Engineering, Cryoglobulinemic vasculitis, CV, Scleroderma, Systemic sclerosi, Systemic lupu, Anti-citrullinated protein antibodies, ACPA, Systemic vasculitis, Lupus Erythematosus, Systemic, Immunology and Allergy, Medicine, Viral, Prospective Studies, Prospective cohort study, Neutralizing, education.field_of_study, Autoimmune systemic diseases, COVID-19 vaccine, Cryoglobulinemic vasculitis, Neutralizing antibodies, Rheumatoid arthritis, Systemic lupus, Systemic sclerosis, Immunogenicity, Vaccination, Middle Aged, Neutralizing antibody, NAb, Rheumatoid factor, RF, Italy, Female, Rituximab, Systemic sclerosis, SSc, Adverse events, AEs, 2019-nCoV Vaccine mRNA-1273, Human, medicine.drug, medicine.medical_specialty, Systemic lupus erythematosus, SLE, Immunology, Population, Autoimmune systemic disease, Autoimmune Disease, Article, Antibodies, Autoimmune Diseases, Internal medicine, Neutralizing antibodie, Humans, Business and International Management, Seroconversion, education, Settore BIO/10 - BIOCHIMICA, Vaccine Potency, Rheumatoid arthriti, BNT162 Vaccine, Scleroderma, Systemic, Lupus Erythematosus, Cryoglobulinemic vasculiti, SARS-CoV-2, business.industry, Systemic, Systemic Vasculiti, COVID-19, medicine.disease, Antibodies, Neutralizing, Autoimmune systemic diseases, ASD, Prospective Studie, World Health Organization, WHO, Rheumatoid arthritis, RA, Systemic Vasculitis, business
Abstract

Autoimmune systemic diseases (ASD) may show impaired immunogenicity to COVID-19 vaccines. Our prospective observational multicenter study aimed to evaluate the seroconversion after the vaccination cycle and at 6-12-month follow-up, as well the safety and efficacy of vaccines in preventing COVID-19. The study included 478 unselected ASD patients (mean age 59 ± 15 years), namely 101 rheumatoid arthritis (RA), 38 systemic lupus erythematosus (SLE), 265 systemic sclerosis (SSc), 61 cryoglobulinemic vasculitis (CV), and a miscellanea of 13 systemic vasculitis. The control group included 502 individuals from the general population (mean age 59 ± 14SD years). The immunogenicity of mRNA COVID-19 vaccines (BNT162b2 and mRNA-1273) was evaluated by measuring serum IgG-neutralizing antibody (NAb) (SARS-CoV-2 IgG II Quant antibody test kit; Abbott Laboratories, Chicago, IL) on samples obtained within 3 weeks after vaccination cycle. The short-term results of our prospective study revealed significantly lower NAb levels in ASD series compared to controls [286 (53–1203) vs 825 (451–1542) BAU/mL, p < 0.0001], as well as between single ASD subgroups and controls. More interestingly, higher percentage of non-responders to vaccine was recorded in ASD patients compared to controls [13.2% (63/478), vs 2.8% (14/502); p < 0.0001]. Increased prevalence of non-response to vaccine was also observed in different ASD subgroups, in patients with ASD-related interstitial lung disease (p = 0.009), and in those treated with glucocorticoids (p = 0.002), mycophenolate-mofetil (p < 0.0001), or rituximab (p < 0.0001). Comparable percentages of vaccine-related adverse effects were recorded among responder and non-responder ASD patients. Patients with weak/absent seroconversion, believed to be immune to SARS-CoV-2 infection, are at high risk to develop COVID-19. Early determination of serum NAb after vaccination cycle may allow to identify three main groups of ASD patients: responders, subjects with suboptimal response, non-responders. Patients with suboptimal response should be prioritized for a booster-dose of vaccine, while a different type of vaccine could be administered to non-responder individuals.

Published
2022

4. COVID-19 and systemic sclerosis: clinicopathological implications from Italian nationwide survey study

Author

Clodoveo Ferri, Dilia Giuggioli, Vincenzo Raimondo, Lorenzo Dagna, Valeria Riccieri, Elisabetta Zanatta, Serena Guiducci, Antonio Tavoni, Rosario Foti, Giovanna Cuomo, Rossella De Angelis, Franco Cozzi, Giuseppe Murdaca, Ilaria Cavazzana, Nicoletta Romeo, Veronica Codullo, Francesca Ingegnoli, Roberta Pellegrini, Giuseppe Varcasia, Alessandra Della Rossa, Maria De Santis, Giuseppina Abignano, Michele Colaci, Maurizio Caminiti, Massimo L'Andolina, Ennio Lubrano, Amelia Spinella, Federica Lumetti, Giacomo De Luca, Silvia Bellando-Randone, Elisa Visalli, Silvia Bilia, Daiana Giannini, Francesco Masini, Greta Pellegrino, Erika Pigatto, Elena Generali, Francesca Dall'Ara, Giuseppa Pagano Mariano, Simone Barsotti, Giorgio Pettiti, Giovanni Zanframundo, Raffaele Brittelli, Vincenzo Aiello, Daniela Scorpiniti, Tommaso Ferrari, Rodolfo Caminiti, Corrado Campochiaro, Salvatore D'Angelo, Florenzo Iannone, Marco Matucci-Cerinic, Andrea Doria, Mario Miccoli, Poupak Fallahi, Alessandro Antonelli, Riccardo Cecchetti, Pietro Gigliotti, Domenico Olivo, Francesco Ursini, Veronica Brusi, Riccardo Meliconi, Raffaele Scarpa, Enrico Fusaro, Anna Linda Zignego, Sabrina Rosaria Paparo, Francesca Ragusa, Giusy Elia, Silvia Martina Ferrari, Ferri, C., Giuggioli, D., Raimondo, V., Dagna, L., Riccieri, V., Zanatta, E., Guiducci, S., Tavoni, A., Foti, R., Cuomo, G., De Angelis, R., Cozzi, F., Murdaca, G., Cavazzana, I., Romeo, N., Codullo, V., Ingegnoli, F., Pellegrini, R., Varcasia, G., Rossa, A. D., De Santis, M., Abignano, G., Colaci, M., Caminiti, M., L'Andolina, M., Lubrano, E., Spinella, A., Lumetti, F., De Luca, G., Bellando-Randone, S., Visalli, E., Bilia, S., Giannini, D., Masini, F., Pellegrino, G., Pigatto, E., Generali, E., Dall'Ara, F., Mariano, G. P., Barsotti, S., Pettiti, G., Zanframundo, G., Brittelli, R., Aiello, V., Scorpiniti, D., Ferrari, T., Caminiti, R., Campochiaro, C., D'Angelo, S., Iannone, F., Matucci-Cerinic, M., Doria, A., Miccoli, M., Fallahi, P., Antonelli, A., Della Rossa, A., Pagano Mariano, G., Cecchetti, R., Gigliotti, P., Olivo, D., Ursini, F., Brusi, V., Meliconi, R., Scarpa, R., Fusaro, E., Zignego, A. L., Paparo, S. R., Ragusa, F., Elia, G., Ferrari, S. M., Ferri C., Giuggioli D., Raimondo V., Dagna L., Riccieri V., Zanatta E., Guiducci S., Tavoni A., Foti R., Cuomo G., De Angelis R., Cozzi F., Murdaca G., Cavazzana I., Romeo N., Codullo V., Ingegnoli F., Pellegrini R., Varcasia G., Rossa A.D., De Santis M., Abignano G., Colaci M., Caminiti M., L'Andolina M., Lubrano E., Spinella A., Lumetti F., De Luca G., Bellando-Randone S., Visalli E., Bilia S., Giannini D., Masini F., Pellegrino G., Pigatto E., Generali E., Dall'Ara F., Mariano G.P., Barsotti S., Pettiti G., Zanframundo G., Brittelli R., Aiello V., Scorpiniti D., Ferrari T., Caminiti R., Campochiaro C., D'Angelo S., Iannone F., Matucci-Cerinic M., Doria A., Miccoli M., Fallahi P., Antonelli A., Della Rossa A., Pagano Mariano G., Cecchetti R., Gigliotti P., Olivo D., Ursini F., Brusi V., Meliconi R., Scarpa R., Fusaro E., Zignego A.L., Paparo S.R., Ragusa F., Elia G., Ferrari S.M., and De Luca, Giacomo.

Subjects
medicine.medical_specialty, 2019-20 coronavirus outbreak, Coronavirus disease 2019 (COVID-19), business.industry, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Immunology, MEDLINE, COVID-19, Nationwide survey, Rheumatology, Family medicine, Systemic sclerosis, Immunology and Allergy, Medicine, business
Abstract

None

Published
2021

5. Covid-19 And Rheumatic Autoimmune Systemic Diseases: Role of Pre-Existing Lung Involvement and Ongoing Treatments

Author

M. L. Aprile, Rosario Foti, Ruscitti Piero, Giuseppe Varcasia, Ilaria Cavazzana, Nicoletta Romeo, Riccardo Meliconi, Serena Lorini, Serena Guiducci, Amelia Spinella, Roberto Giacomelli, Vincenzo Aiello, Alessandra Della Rossa, Giorgio Amato, Daiana Giannini, Vincenzo Raimondo, Francesco Caso, Ennio Lubrano, Silvia Bosello, Maurizio Caminiti, Monica Monti, Tasso Marco, Francesca Ingegnoli, Giorgio Pettiti, Massimo L'Andolina, Salvatore D'Angelo, Francesca Ragusa, Elisabetta Zanatta, Giacomo De Luca, Riccardo Cecchetti, Franco Franceschini, Greta Pellegrino, Silvia Bellando-Randone, Silvia Martina Ferrari, Micaela Fredi, Veronica Brusi, Lorenzo Dagna, Giusy Elia, Fabio Cacciapaglia, Francesco Ursini, Giuseppina Abignano, Sebastiano Lorusso, Clodoveo Ferri, Anna Linda Zignego, Rodolfo Caminiti, Sabrina Rosaria Paparo, Raffaele Brittelli, Liala Moschetti, Elena Generali, Marco Matucci-Cerinic, Roberta Pellegrini, Ylenia Dal Bosco, Giovanni Zanframundo, Domenico Olivo, Tommaso Ferrari, Alessandro Antonelli, M. Vadacca, Andrea Doria, Pietro Gigliotti, Poupak Varcasia, Enrico Fusaro, Elisa Visalli, Simone Barsotti, Giuseppa Pagano Mariano, Giovanna Cuomo, Florenzo Iannone, Maria De Santis, Valeria Mazzi, Giuseppe Murdaca, Michele Colaci, Silvia Bilia, Franco Cozzi, Dilia Giuggioli, Corrado Campochiaro, Valeria Riccieri, Erika Pigatto, Laura Gragnani, Ilenia Di Cola, Daniela Scorpiniti, Mario Miccoli, Francesco Masini, Veronica Codullo, Rossella De Angelis, Federica Lumetti, Antonio Tavoni, Ferri, Clodoveo, Giuggioli, Dilia, Raimondo, Vincenzo, L’Andolina, Massimo, Dagna, Lorenzo, Tavoni, Antonio, Caso, Francesco, Ursini, Francesco, Piero, Ruscitti, Caminiti, Maurizio, Foti, Rosario, Riccieri, Valeria, Guiducci, Serena, Pellegrini, Roberta, Zanatta, Elisabetta, Varcasia, Giuseppe, Olivo, Domenico, Gigliotti, Pietro, Cuomo, Giovanna, Murdaca, Giuseppe, Cecchetti, Riccardo, De Angelis, Rossella, Romeo, Nicoletta, Ingegnoli, Francesca, Cozzi, Franco, Codullo, Veronica, Cavazzana, Ilaria, Colaci, Michele, Abignano, Giuseppina, De Santis, Maria, Lubrano, Ennio, Fusaro, Enrico, Rossa, Alessandra Della, Spinella, Amelia, Lumetti, Federica, De Luca, Giacomo, Bellando-Randone, Silvia, Visalli, Elisa, Dal Bosco, Ylenia, Amato, Giorgio, Giannini, Daiana, Bilia, Silvia, Masini, Francesco, Pellegrino, Greta, Pigatto, Erika, Generali, Elena, Mariano, Giuseppa Pagano, Pettiti, Giorgio, Zanframundo, Giovanni, Brittelli, Raffaele, Aiello, Vincenzo, Caminiti, Rodolfo, Scorpiniti, Daniela, Ferrari, Tommaso, Campochiaro, Corrado, Brusi, Veronica, Fredi, Micaela, Moschetti, Liala, Cacciapaglia, Fabio, Gragnani, Laura, Monti, Monica, Lorini, Serena, Paparo, Sabrina Rosaria, Ragusa, Francesca, Mazzi, Valeria, Elia, Giusy, Ferrari, Silvia Martina, Di Cola, Ilenia, Vadacca, Marta, Lorusso, Sebastiano, Barsotti, Simone, Aprile, Maria Letizia, Marco, Tasso, Miccoli, Mario, Bosello, Silvia, Matucci-Cerinic, Marco, D'Angelo, Salvatore, Doria, Andrea, Franceschini, Franco, Meliconi, Riccardo, Iannone, Florenzo, Giacomelli, Roberto, Zignego, Anna Linda, Varcasia, Poupak, Antonelli, Alessandro, L'Andolina, Massimo, Della Rossa, Alessandra, Pagano Mariano, Giuseppa, Rosaria Paparo, Sabrina, Martina Ferrari, Silvia, Letizia Aprile, Maria, Linda Zignego, Anna, Ferri C., Giuggioli D., Raimondo V., L'andolina M., Dagna L., Tavoni A., Caso F., Ursini F., Ruscitti P., Caminiti M., Foti R., Riccieri V., Guiducci S., Pellegrini R., Zanatta E., Varcasia G., Olivo D., Gigliotti P., Cuomo G., Murdaca G., Cecchetti R., De Angelis R., Romeo N., Ingegnoli F., Cozzi F., Codullo V., Cavazzana I., Colaci M., Abignano G., De Santis M., Lubrano E., Fusaro E., Della Rossa A., Spinella A., Lumetti F., De Luca G., Bellando-Randone S., Visalli E., Dal Bosco Y., Amato G., Giannini D., Bilia S., Masini F., Pellegrino G., Pigatto E., Generali E., Mariano G.P., Pettiti G., Zanframundo G., Brittelli R., Aiello V., Caminiti R., Scorpiniti D., Ferrari T., Campochiaro C., Brusi V., Fredi M., Moschetti L., Cacciapaglia F., Gragnani L., Monti M., Lorini S., Paparo S.R., Ragusa F., Mazzi V., Elia G., Ferrari S.M., Di Cola I., Vadacca M., Lorusso S., Barsotti S., Aprile M.L., Marco T., Miccoli M., Bosello S., Matucci-Cerinic M., D'angelo S., Doria A., Franceschini F., Meliconi R., Iannone F., Giacomelli R., Zignego A.L., Fallahi P., and Antonelli A.

Subjects
medicine.medical_specialty, Settore MED/16 - REUMATOLOGIA, Referral, Coronavirus disease 2019 (COVID-19), autoimmune systemic disease, systemic sclerosis, Population, COVID-19, SARS-CoV-2, arthritis, autoimmune systemic diseases, connective tissue diseases, interstitial lung disease, rheumatic diseases, Arthritis, Keywords: COVID-19, Scleroderma, Autoimmune Diseases, Covid-19, Autoimmune systemic diseases, Connective tissue diseases, Interstitial lung disease, Rheumatic diseases, Systemic sclerosis, Internal medicine, Rheumatic Diseases, Drug Discovery, Pandemic, medicine, Humans, education, rheumatic disease, Lung, Pandemics, Pharmacology, education.field_of_study, Aspirin, business.industry, covid 19, medicine.disease, arthriti, connective tissue disease, business, medicine.drug
Abstract

Background: The Covid-19 pandemic may have a deleterious impact on patients with autoimmune systemic diseases (ASD) due to their deep immune-system alterations. Objective: This study aims to investigate the prevalence of symptomatic Covid-19 and its correlations with both organ involvement and ongoing treatments in a large series of Italian ASD patients during the first wave of pandemic. Methods: Our multicenter telephone 6-week survey included 3,029 unselected ASD patients enrolled at 36 tertiary referral centers of northern, central, and southern Italian macro-areas with different diffusion of the pandemic. Symptomatic SARS-CoV-2 infection was classified as definite Covid-19 (presence of symptoms plus positive oral/nasopharyngeal swabs) or highly suspected Covid-19 (highly suggestive symptoms, in the absence of a swab testing). Results: A significantly higher prevalence of definite plus highly suspected Covid-19 compared to the Italian general population was detected in the whole ASD series (p=.000), as well as in patients from the three macro-areas (p=.000 in all). Statistically higher prevalence of Covid-19 was also found in connective tissue diseases compared to chronic arthritis subgroup (p=.000) and in ASD patients with pre-existing interstitial lung involvement (p=.000). Patients treated with either conventional disease-modifying anti-rheumatic drugs (DMARDs) and/or biological DMARDs showed a significantly lower prevalence of Covid-19 (p=.000 in both). Finally, scleroderma patients undergoing low-dose aspirin showed a significantly lower rate of Covid-19 compared to those without (p=0.003). Conclusion: The higher prevalence of Covid-19 in ASD patients, along with the significant correlations with important clinical features and therapeutic regimens, suggests the need to develop targeted prevention/management strategies during the current pandemic wave.

Published
2021

6. COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series

Author

Giuseppa Pagano Mariano, Maurizio Caminiti, Alessandro Antonelli, Vincenzo Aiello, Dilia Giuggioli, Tommaso Ferrari, Massimo L'Andolina, Michele Colaci, Rodolfo Caminiti, Serena Guiducci, Silvia Bilia, Raffaele Brittelli, Daiana Giannini, Domenico Olivo, Giuseppe Varcasia, Veronica Brusi, Riccardo Meliconi, Vincenzo Raimondo, Amelia Spinella, Poupak Fallahi, Pietro Gigliotti, Clodoveo Ferri, Roberta Pellegrini, Giuseppe Murdaca, Silvia Bellando-Randone, R. Cecchetti, Antonio Tavoni, Francesco Ursini, Ferri C., Giuggioli D., Raimondo V., L'Andolina M., Tavoni A., Cecchetti R., Guiducci S., Ursini F., Caminiti M., Varcasia G., Gigliotti P., Pellegrini R., Olivo D., Colaci M., Murdaca G., Brittelli R., Mariano G.P., Spinella A., Bellando-Randone S., Aiello V., Bilia S., Giannini D., Ferrari T., Caminiti R., Brusi V., Meliconi R., Fallahi P., and Antonelli A.

Subjects
0301 basic medicine, Male, Systemic disease, Arthritis, Autoimmune systemic diseases, Connective tissue diseases, COVID-19, Rheumatic diseases, SARS-CoV-2, Inflammatory arthritis, Psoriatic, Disease, Scleroderma, Arthritis, Rheumatoid, 0302 clinical medicine, Glucocorticoid, Rheumatoid, 80 and over, Medicine, Lupus Erythematosus, Systemic, Viral, Aged, 80 and over, education.field_of_study, Undifferentiated connective tissue disease, Antirheumatic Agent, General Medicine, Middle Aged, Sjogren's Syndrome, Italy, Adult, Aged, Antirheumatic Agents, Arthritis, Psoriatic, Autoimmune Diseases, Betacoronavirus, Coronavirus Infections, Dermatomyositis, Female, Glucocorticoids, Humans, Pandemics, Pneumonia, Viral, Rheumatic Diseases, Scleroderma, Systemic, Spondylitis, Ankylosing, Undifferentiated Connective Tissue Diseases, Original Article, Arthriti, Human, Ankylosing, medicine.medical_specialty, Population, Autoimmune systemic disease, Autoimmune Disease, Rheumatic Disease, 03 medical and health sciences, Rheumatology, Internal medicine, education, Connective tissue disease, 030203 arthritis & rheumatology, Dermatomyositi, Betacoronaviru, Pandemic, Lupus Erythematosus, business.industry, Coronavirus Infection, Systemic, Pneumonia, medicine.disease, 030104 developmental biology, business, Spondylitis
Abstract

IntroductionCovid-19 infection poses a serious challenge for immune-compromised patients with inflammatory autoimmune systemic diseases. We investigated the clinical-epidemiological findings of 1641 autoimmune systemic disease Italian patients during the Covid-19 pandemic.MethodThis observational multicenter study included 1641 unselected patients with autoimmune systemic diseases from three Italian geographical areas with different prevalence of Covid-19 [high in north (Emilia Romagna), medium in central (Tuscany), and low in south (Calabria)] by means of telephone 6-week survey. Covid-19 was classified as (1)definitediagnosis of Covid-19 disease: presence of symptomatic Covid-19 infection, confirmed by positive oral/nasopharyngeal swabs; (2)highly suspectedCovid-19 disease: presence of highly suggestive symptoms, in absence of a swab test.ResultsA significantly higher prevalence of patients withdefinitediagnosis of Covid-19 disease,or withhighly suspectedCovid-19 disease, or both the conditions together, was observed in the whole autoimmune systemic disease series, compared to “Italian general population” (p = .030,p = .001,p = .000, respectively); and fordefinite + highly suspecteddiagnosis of Covid-19 disease, in patients with autoimmune systemic diseases of the three regions (p = .000, for all comparisons with the respective regional general population).Moreover, significantly higher prevalence ofdefinite + highly suspecteddiagnosis of Covid-19 disease was found either in patients with various “connective tissue diseases” compared to “inflammatory arthritis group” (p p = .011).ConclusionsThe finding of a higher prevalence of Covid-19 in patients with autoimmune systemic diseases is particularly important, suggesting the need to develop valuable prevention/management strategies, and stimulates in-depth investigations to verify the possible interactions between Covid-19 infection and impaired immune-system of autoimmune systemic diseases.Key Points• Significantly higher prevalence of Covid-19 is observed in a large series of patients with autoimmune systemic diseases compared to the Italian general population, mainly due to patients’ increased susceptibility to infections and favored by the high exposure to the virus at medical facilities before the restriction measures on individual movement.• The actual prevalence of Covid-19 in autoimmune systemic diseases may be underestimated, possibly due to the wide clinical overlapping between the two conditions, the generally mild Covid-19 disease manifestations, and the limited availability of virological testing.• Patients with “connective tissue diseases” show a significantly higher prevalence of Covid-19, possibly due to deeper immune-system impairment, with respect to “inflammatory arthritis group”.• Covid-19 is more frequent in the subgroup of autoimmune systemic diseases patients without ongoing conventional synthetic disease-modifying anti-rheumatic drugs, mainly hydroxyl-chloroquine and methotrexate, which might play some protective role against the most harmful manifestations of Covid-19.

Published
2020

7. Implementing a simple pharmacovigilance program to improve reporting of adverse events associated with biologic therapy in rheumatology: Preliminary results from the Calabria Biologics Pharmacovigilance Program (CBPP)

Author

Domenico Olivo, Karim Abdalla, Rita Citraro, Giuseppa Pagano Mariano, Pietro Gigliotti, Antonia Manti, Christian Leporini, Massimo L'Andolina, Rosa Daniela Grembiale, Maria Diana Naturale, Roberta Pellegrini, Maurizio Caminiti, Giovambattista De Sarro, Giuseppe Varcasia, Giuseppe Muccari, Caterina Palleria, Emilio Russo, Francesco Ursini, Luigi Francesco Iannone, Palleria C., Iannone L., Leporini C., Citraro R., Manti A., Caminiti M., Gigliotti P., Grembiale R.D., L'Andolina M., Muccari G., Naturale M.D., Olivo D., Mariano G.P., Pellegrini R., Varcasia G., Abdalla K., Russo E., Ursini F., and De Sarro G.

Subjects
Male, Medical Doctors, NSAIDs, Health Care Providers, pharmacovigilance biologics arthritis, lcsh:Medicine, Geographical locations, law.invention, Pharmacovigilance, 0302 clinical medicine, law, Injection site, Medicine and Health Sciences, 030212 general & internal medicine, Medical Personnel, lcsh:Science, Analgesics, Multidisciplinary, Clinical pharmacology, Drug Substitution, Clinical Pharmacology, Drugs, Middle Aged, Europe, Biological Therapy, Professions, Italy, Research Design, Spontaneous reporting, Antirheumatic Agents, Cohort, Female, Research Article, Preliminary Data, medicine.medical_specialty, Drug Research and Development, Clinical Research Design, Psoriatic Arthritis, Research and Analysis Methods, NO, 03 medical and health sciences, Psoriatic arthritis, Drug Safety, Rheumatology, Internal medicine, Physicians, medicine, Adverse Drug Reaction Reporting Systems, Humans, European Union, Adverse effect, 030203 arthritis & rheumatology, Pharmacology, pharmacovigilance, biologics, Biological Products, business.industry, Arthritis, lcsh:R, medicine.disease, Pain management, Health Care, Emergency medicine, lcsh:Q, Population Groupings, Adverse Events, People and places, business, Follow-Up Studies
Abstract

Introduction Post-marketing surveillance activities (namely pharmacovigilance) are crucial to favor the early detection of unexpected adverse events (AEs) and/or serious adverse reactions (SAEs). Indeed, spontaneous reporting of AEs has been demonstrated to underestimate the number of events in different clinical settings. Aim of the present study is to report the preliminary data of a Regional (Calabria, Italy) Pharmacovigilance Program (CBPP) aimed at improving AEs’ reporting associated with biologics use in rheumatology. Materials and methods We developed a simple, cost-effective pharmacovigilance program based on regular training sessions for physicians (stimulated reporting), periodical phone calls by a clinical pharmacologist aimed at identifying new events and stimulating self-awareness and encouraging reporting to the physician during the subsequent follow-up visit for minor AEs. To test this approach, all consecutive patients undergoing treatment with one biologic agent at eight rheumatology centers during a two-years period were invited to participate. Collected AEs were compared to the number of AEs spontaneously reported for the same molecules in the same centers before starting the protocol. Results During the study period, 399 patients (245 females; mean age: 58 ± 11 years) were started on treatment with biologics for active RA (n = 211, 52.9%), PsA (n = 119, 29.8%) or AS (n = 69, 17.3%) at eight rheumatology centers. A total of 125 AEs (31.3%) and 9 SAEs (2.3%) were reported during the two-years study period. In the control cohort (comprising 368 consecutive patients started on treatment with bDMARDs during a two-years period before CBPP study) only 42 (11.4%) AEs and no SAEs were reported (p < 0.0001). The most common AEs were injection site reactions and skin disorders. Conclusions In conclusion, our study provides further evidence of a critical role of active pharmacovigilance in detection, reporting and analysis of AEs in rheumatology.

Published
2018

8. Elective bone marrow transplantation in a child with X-linked hyper-IgM syndrome presenting with acute respiratory distress syndrome

Author

Valentina Leone, Alessandro Ventura, G Runti, U. De Vonderweid, M. Andolina, Alberto Tommasini, C Campello, Lucia Dora Notarangelo, Leone, V, Tommasini, Alberto, Andolina, M, Runti, G, DE VONDERWEID, Umberto, Campello, C, Notarangelo, Ld, and Ventura, Alessandro

Subjects
Homologous, Male, Pediatrics, medicine.medical_specialty, ARDS, bone marrow transplantation, surfactant, T-Lymphocytes, CD40 Ligand, Article, Bone Marrow Transplantation, CD40 Ligand, Genetic Disease, X-linked hyper-IgM syndrome, Hypergammaglobulinemia, medicine, Humans, Transplantation, Homologous, Immunodeficiency, Pneumocystis, Syndrome, T-Lymphocytes, Transplantation, Transplantation, Respiratory distress, business.industry, Pneumocystis, Pneumonia, Pneumocystis, Respiratory disease, Infant, Genetic Diseases, X-Linked, Hematology, Pneumonia, Syndrome, X-Linked, acute respiratory distress syndrome, medicine.disease, Bone Marrow Transplantation, CD40 Ligand, Genetic Diseases, X-Linked, Humans, Hypergammaglobulinemia, Immunoglobulin M, Infant, Male, Pneumonia, Surgery, medicine.anatomical_structure, Pneumocystis carinii, Immunoglobulin M, Genetic Diseases, Bone marrow, Complication, business
Abstract

We describe a 10-month-old boy diagnosed with X-linked hyper-IgM syndrome (XHIM) after suffering from life-threatening acute respiratory distress syndrome (ARDS) caused by Pneumocystis carinii pneumonia (PCP), although his previous clinical history and first level laboratory tests investigating immunological function did not indicate immunodeficiency. When the patient's overall condition was good, elective bone marrow transplantation from an HLA-matched older brother was performed successfully. We describe how correct diagnosis and successful treatment were made possible thanks to the involvement of a network of specialists.

Published
2002

9. The immunosuppressive effect of Wharton's jelly stromal cells depends on the timing of their licensing and on lymphocyte activation

Author

Erica Valencic, Alberto Tommasini, M. Andolina, Elisa Piscianz, Alessandro Ventura, Valencic, E, Piscianz, Elisa, Andolina, M, Ventura, Alessandro, and Tommasini, A.

Subjects
Cancer Research, Time Factors, Stromal cell, Time Factor, medicine.medical_treatment, Immunology, Stimulation, Cell Count, Lymphocyte Activation, Immune tolerance, Umbilical Cord, Mesoderm, Interferon-gamma, Wharton's jelly, immunosuppressive effect, medicine, Immune Tolerance, Humans, Immunology and Allergy, Interferon gamma, Phytohemagglutinins, Indoleamine 2,3-dioxygenase, Cell Proliferation, Cytokines, Stromal Cells, Subcellular Fractions, Tryptophan, Cytokine, Genetics (clinical), Transplantation, business.industry, Mesenchymal stem cell, Stromal Cell, Immunosuppression, Cell Biology, Phytohemagglutinin, stromal cells, lymphocyte activation, Subcellular Fraction, Oncology, business, medicine.drug, Human
Abstract

Background . Mesenchymal stromal cells (MSC) have been proven to have potent immunosuppressive action and hence have been proposed for the treatment of severe Graft Versus Host Disease. However, in most models, MSC were added at the same time of lymphocyte stimulation, which is quite different from what occurs in vivo. Aims. To investigate how the timing of lymphocyte activation and the exposure to activation-related cytokines (licensing) can infl uence the immunosuppressive action of Wharton’s jelly stromal cells (WJSC). Methods. WJSC, licensed or not with activation-related cytokines, were added lymphocytes the same time or 24 hours after their stimulation with phytohaemoagglutinin. Proliferation of lymphocytes and cytokines production was measured after three days co-culture. Results . Lymphocytes stimulated in the presence of WJSC displayed a dramatic decrease in proliferation and production of cytokines, in spite of normal expression of activation markers. The suppression was weakened when targeted lymphocytes were seperated by a membrane and partially rescued by the addition of exogenous L-tryptophan, suggesting a major role for indoleamine 2,3-dioxigenase with a probable paracrine effect. Licensing of WJSC increased the immunosuppressive effect, in both contact and non-contact settings. The timing of WJSC licensing was crucial for the immunosuppressive action. Lymphocytes pre-stimulated alone for 24 h, and added afterwards to non-licensed WJSC, showed normal or even increased proliferation. On the other hand, their proliferation was strongly inhibited by licensed WJSC. Conclusions . WJSC have a potent immunosuppressive function best realized with direct contact, and increased by licensing signals before and during lymphocyte stimulation. Our results could contribute to the set up of new WJSC-based therapies for severe autoimmuno disorders.

Published
2010

10. Avascular necrosis of bone in children undergoing allogeneic bone marrow transplantation

Author

Giulio Andrea Zanazzo, Elia Accorsi, Paolo Tamaro, Maurizio Mascarin, Maria Giavitto, Marino Andolina, Maria Assunta Cova, Mascarin, M, Giavitto, M, Zanazzo, Ga, Andolina, M, Cova, MARIA ASSUNTA, Accorsi, E, and Tamaro, Paolo

Subjects
Male, Cancer Research, medicine.medical_specialty, Cyclophosphamide, Combination therapy, Avascular necrosis, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Child, Bone Marrow Transplantation, Leukemia, medicine.diagnostic_test, business.industry, Marrow transplantation, Osteonecrosis, Magnetic resonance imaging, Total body irradiation, medicine.disease, Combined Modality Therapy, Magnetic Resonance Imaging, Surgery, Transplantation, Oncology, Methotrexate, business, Whole-Body Irradiation, medicine.drug
Abstract

Avascular necrosis of bone (AVNB) is reported in two children after allogeneic bone marrow transplantation. Preparation therapy for transplantation included cyclophosphamide and total body irradiation. Corticosteroids, cyclosporine A, and methotrexate were used for graft-versus-host-disease prophylaxis. The possible role of combination therapy in development of AVNB is discussed, but a direct relationship with single agents was not found. However, an early diagnosis is important to institute conservative treatment and prevent irreversible damage to affected joints. Magnetic resonance imaging was found to be more sensitive than plain radiography in early detection of AVNB.

Published
1991
Full Text
View/download PDF

11. Medium-term survival without haematopoietic stem cell transplantation in a case of IPEX: insights into nutritional and immunosuppressive therapy

Author

Egidio Barbi, Alberto Tommasini, Andrea Taddio, Erica Valencic, Alessandro Ventura, M. Andolina, Marilena Granzotto, Elena Faleschini, Loredana Lepore, Taddio, Andrea, Faleschini, E, Valencic, Erica, Granzotto, M, Tommasini, Alberto, Lepore, L, Andolina, M, Barbi, E, and Ventura, Alessandro

Subjects
Male, Diet therapy, Autoimmunity, medicine.disease_cause, IPEX, Immunodeficiency, Treatment, HSCT, Autoimmune Diseases, Medium term, medicine, Humans, Combined Modality Therapy, Nutritional Support, business.industry, Infant, Forkhead Transcription Factors, medicine.disease, Anti-Bacterial Agents, Transplantation, Haematopoiesis, Pediatrics, Perinatology and Child Health, Immunology, Steroids, Stem cell, business, Immunosuppressive Agents
Abstract

This work studies IPEX (Immunodysregulation with Polyendocrinopathy and Enteropathy X-linked), a severe disorder of course in early childhood due to mutations in the FOXP3 gene (locus Xp11.23-q13.3) leading to failure in immune tolerance and his theraphy with HSCT (Haematopoietic stem cell transplantation).

Published
2007

12. Transplant-related toxicity and mortality: An AIEOP prospective study in 636 pediatric patients transplanted for acute leukemia

Author

Roberto Rondelli, Cornelio Uderzo, Edoardo Lanino, C De Fusco, Daniela Silvestri, A. P. Iori, M. Andolina, Franca Fagioli, Maria Grazia Valsecchi, Attilio Rovelli, Francesco Locatelli, Claudio Favre, Alessandro Busca, L Manfredini, Adriana Balduzzi, Chiara Messina, Fulvio Porta, Giovanna Giorgiani, Arcangelo Prete, S Ceppi, Balduzzi, A, Valsecchi, M, Silvestri, D, Locatelli, F, Manfredini, L, Busca, A, Iori, A, Messina, C, Prete, A, Andolina, M, Porta, F, Favre, C, Ceppi, S, Giorgiani, G, Lanino, E, Rovelli, A, Fagioli, F, De Fusco, C, Rondelli, R, and Uderzo, C

Subjects
Male, Registrie, Transplant-related mortality, medicine.medical_treatment, Hematopoietic stem cell transplantation, Gastroenterology, Severity of Illness Index, Risk Factors, Prospective Studies, Registries, Chronic, Prospective cohort study, Child, Transplantation, Homologou, Acute leukemia, Leukemia, Hematopoietic Stem Cell Transplantation, Transplant-Related Mortality, Hematology, Transplantation, Autologou, Organ Specificity, Child, Preschool, Toxicity, Female, Survival Analysi, Bone marrow transplantation, Childhood, Transplant related toxicity, Adolescent, Humans, Infant, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Survival Analysis, Transplantation, Autologous, Transplantation, Homologous, Transplantation, Autologous, Human, Homologous, medicine.medical_specialty, Acute lymphocytic leukemia, Internal medicine, medicine, Preschool, Survival analysis, business.industry, Risk Factor, medicine.disease, Surgery, Prospective Studie, BCR-ABL Positive, business, Myelogenous
Abstract

Hematopoietic stem cell transplantation can cure high-risk acute leukemia (AL), but the occurrence of non-leukemic death is still high. The AIEOP conducted a prospective study in order to assess incidence and relationships of early toxicity and transplant-related mortality (TRM) in a pediatric population. Between 1990 and 1997 toxicities reported in eight organs (central nervous system, heart, lungs, liver, gut, kidneys, bladder, mucosa) were classified into three grades (mild, moderate, severe) and prospectively registered for 636 consecutive children who underwent autologous (216) or allogeneic (420) transplantation, either from an HLA compatible related (294), or alternative (126) donor in 13 AIEOP transplant centers. Overall, 47% of the patients are alive in CR (3-year EFS: 45.2%, s.e.: 2.1), 19% died in CR at a median of 60 days (90-day TRM: 14.3%, s.e.: 1.4), 34% relapsed. Toxicity of any organ, but mucosa and gut, was positively correlated with early death; moderate and severe toxicity to heart, lungs, liver and kidneys significantly increased early TRM, with estimated relative risks of 9.1, 5.5, 2.7 and 2.8, respectively, as compared to absent or mild toxicity. Patients with grade III-IV aGVHD experienced more than double (56% vs. 19%) TRM than patients with grade 0-II aGVHD. A higher cumulative toxicity score, estimating the impact of toxicity on TRM, was significantly associated with transplantation from an alternative donor. Quantitative assessment allowed us to describe the extent to which 'grade' of toxicity and 'type' of involved organs were related to mortality and pre-transplant characteristics and yielded a prognostic score potentially useful to compare different conditioning regimens and predict probability of early death.

Published
2002

13. STRIP AGA TEST: A RAPID AND ACCURATE METHOD IN SCREENING FOR COELIAC DISEASE

Author

Tarcisio Not, Giuliano Torre, M Bittolo, Alessandro Ventura, M Andolina, Not, Tarcisio, Ventura, Alessandro, Bittolo, M, Torre, G, and Andolina, M.

Subjects
education.field_of_study, biology, business.industry, Population, Venous blood sample, Chronic diarrhoea, medicine.disease, Coeliac disease, Pediatrics, Perinatology and Child Health, Elisa test, Immunology, medicine, biology.protein, Gluten free, Antibody, business, education, Whole blood
Abstract

Antialfagliadin antibodies(AGA)are a useful tool in screening for Coeliac Disease (CD). Anyway, this test requires a rather specialized laboratory, a venous blood sample and about one week in order to obtain the result for the “family” paediatrician. We developed and evaluated a dot immunobinding assay to detect alfagliadin IgG and IgA antibodies in a single drop of whole blood. The method is based on the absorption of alfa-gliadin as a spot on to nitrocellulose sheets, who are immobilized on plastic strips. The strips were incubated 30' with patient sample, and 30' with alkaline phospatase conjugate antihuman (IgA and IgG)antibodies. After short incubation(15')with the substrate solution, the strip was dried and finally examined for the results, which are expressed by a colorimetric reaction. Twenty patients with CD(10 with active disease, 10 during gluten free diet(GFD)), 11 children with other gastrointestinal diseases( 8 IBD, 1 autoimmune chronic diarrhoea, 1 congenital microvillous atrophy, 1 unexplained chronic diarrhoea) and 35 healty controls were examined with both strip AGA test and the classic ELISA test for AGA. The results are summarized as follows: The method showed good correspondence with ELISA AGA test: the procedure is quick and simple and does not requires any costly equipment. We think that this “Strip AGA test” could be very convenient both for screening and for the follow-up of CD. This test could also be useful in population and/or family screening for C.D.

Published
1990
Full Text
View/download PDF

14. 'Successful therapy of Niemann-Pick disease by implantation of human amniotic membrane'

Author

Bruna Scaggiante, Alberto Pineschi, Massimo Sustersich, Domenico Romeo, Marino Andolina, Eriberto Agosti, Scaggiante, Bruna, Pineschi, A., Sustersich, M, Andolina, M., Agosti, E., and AND ROMEO, D.

Subjects
Male, Cell type, medicine.medical_specialty, Pathology, Adolescent, Epithelium, Pregnancy, Internal medicine, Medicine, Humans, Amnion, Niemann-Pick Diseases, Transplantation, business.industry, Phosphoric Diester Hydrolases, Graft Survival, Enzyme replacement therapy, medicine.disease, Endocrinology, medicine.anatomical_structure, Sphingomyelin Phosphodiesterase, Host vs Graft Reaction, Female, business, Niemann–Pick disease
Abstract

In a patient with a lysosomal storage disorder, not involving the CNS, repeated implantations of human amniotic sheets have proved to provide a successful approach to enzyme replacement therapy. Implantation of pure epithelial cells, separated from the other cell types of the amnion, might markedly improve the procedure, avoiding some risks of host-versus-graft rejection.

Published
1987

Catalog

Books, media, physical & digital resources
See catalog results